Philippe ROCHIGNEUX

29
Documents
Identifiants chercheurs

Présentation

Publications

1
2
9
2
1
8
4
2
5
4
3
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Publications

Deposit thumbnail

Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management

Essia Mezni , Giovanni Corazza , Roxane Mari , Stephanie Coze , Nathalie Charrier et al.

Frontiers in Immunology, 2024, 15, ⟨10.3389/fimmu.2024.1375497⟩

Article dans une revue hal-05141525v1
Deposit thumbnail

Impact of fiducial markers placement on the delineation of target volumes in radiation therapy for oesophageal cancer: FIDUCOR study

Philippe Rochigneux , Marguerite Tyran , Aurélie Autret , Leonor Lopez Almeida , Jérôme Guiramand et al.

Frontiers in Oncology, 2022, 12, ⟨10.3389/fonc.2022.1012712⟩

Article dans une revue hal-03869102v1
Deposit thumbnail

Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial

Clélia Coutzac , Frédéric Bibeau , Méher Ben Abdelghani , Thomas Aparicio , Romain Cohen et al.

Digestive and Liver Disease, 2022, 54 (10), pp.1335-1341. ⟨10.1016/j.dld.2022.07.008⟩

Article dans une revue hal-03837196v1

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma

Emilien Billon , Brice Chanez , Philippe Rochigneux , Laurence Albiges , Cécile Vicier et al.

Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.670827⟩

Article dans une revue hal-03623028v1

High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome

Anne-Sophie Chretien , Raynier Devillier , Samuel Granjeaud , Charlotte Cordier , Clemence Demerle et al.

Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 (22), pp.e2020459118. ⟨10.1073/pnas.2020459118⟩

Article dans une revue hal-03565991v1

739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Renaud Sabatier , Cécile Vicier , Séverine Garnier , Arnaud Guille , Nadine Carbuccia et al.

Annals of Oncology, 2021, 32 (15_suppl), pp.S737-S738. ⟨10.1016/j.annonc.2021.08.1181⟩

Article dans une revue hal-03622737v1
Deposit thumbnail

Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology

Sandrine Rousset-Rouviere , Philippe Rochigneux , Anne-Sophie Chrétien , Stéphane Fattori , Laurent Gorvel et al.

Biomedicines, 2021, 9 (6), pp.632. ⟨10.3390/biomedicines9060632⟩

Article dans une revue hal-03622756v1
Deposit thumbnail

Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2+ γδ T Cell Alterations with Lymph Node Invasion

Stéphane Fattori , Laurent Gorvel , Samuel Granjeaud , Philippe Rochigneux , Marie-Sarah Rouvière et al.

Cancers, 2021, 13 (3), pp.441. ⟨10.3390/cancers13030441⟩

Article dans une revue hal-03152759v1

Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

Nanruoyi Zhou , Maria Velez , Benjamin Bachrach , Jaklin Gukasyan , Charlene Fares et al.

Lung Cancer, 2021, 161, pp.34-41. ⟨10.1016/j.lungcan.2021.08.009⟩

Article dans une revue hal-03689919v1

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

Philippe Rochigneux , Brice Chanez , Bernadette de Rauglaudre , Emmanuel Mitry , Christian Chabannon et al.

Cancers, 2021, 13 (2), pp.271. ⟨10.3390/cancers13020271⟩

Article dans une revue hal-03689931v1

Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report

Julie Leblanc , Solene Hoibian , Agathe Boucraut , Jean-Philippe Ratone , Louis Stoffaes et al.

Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.799666⟩

Article dans une revue hal-03689905v1
Deposit thumbnail

Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study

Brice Chanez , Fabrice Caillol , Jean-Philippe Ratone , Christian Pesenti , Philippe Rochigneux et al.

Cancers, 2021, 13 (21), pp.5267. ⟨10.3390/cancers13215267⟩

Article dans une revue hal-03689914v1
Deposit thumbnail

Les glycosylations de PD-L1 sous les feux de la rampe

Daniel Olive , Anne-Sophie Chrétien , Raynier Devillier , Philippe Rochigneux , Laurent Gorvel et al.

Médecine/Sciences, 2020, 36 (6-7), pp.552-555. ⟨10.1051/medsci/2020099⟩

Article dans une revue hal-02903988v1
Deposit thumbnail

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

Philippe Rochigneux , Alejandro Garcia , Brice Chanez , Anne Madroszyk , Daniel Olive et al.

Frontiers in Immunology, 2020, 11, ⟨10.3389/fimmu.2020.01036⟩

Article dans une revue hal-03152719v1
Deposit thumbnail

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review

Gabrielle Planes-Laine , Philippe Rochigneux , François Bertucci , Anne-Sophie Chrétien , Patrice Viens et al.

Cancers, 2019, 11 (7), pp.1033. ⟨10.3390/cancers11071033⟩

Article dans une revue (article de synthèse) hal-02533030v1

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

Philippe Rochigneux , Jeanne Thomassin-Piana , Sophy Laibe , Serge Brunelle , Naji Salem et al.

BMC Cancer, 2018, 18 (1), pp.1159. ⟨10.1186/s12885-018-5049-3⟩

Article dans une revue hal-03689938v1
Deposit thumbnail

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors

Marjorie Faure , Philippe Rochigneux , Daniel Olive , Sebastien Taix , Isabelle Brenot-Rossi et al.

Frontiers in Immunology, 2018, 9, ⟨10.3389/fimmu.2018.00797⟩

Article dans une revue hal-02143544v1

Acute myositis

Philippe Rochigneux , Nicolas Schleinitz , Mikael Ebbo , Marie Aymonier , Bertrand Pourroy et al.

Anti-Cancer Drugs, 2018, 29 (5), pp.477-481. ⟨10.1097/CAD.0000000000000620⟩

Article dans une revue hal-03689955v1

Are lung adenocarcinoma mutations shaping the immune microenvironment?

Philippe Rochigneux , Edward B. Garon

Translational Cancer Research, 2018, 7 (7), pp.S740-S742. ⟨10.21037/tcr.2018.07.17⟩

Article dans une revue hal-02143662v1

Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma

Philippe Rochigneux , Jean-Charles Nault , Françoise Mallet , Anne-Sophie Chretien , Nathalie Barget et al.

Annals of Oncology, 2018, 29 (10), pp.7. ⟨10.1080/2162402X.2019.1615818⟩

Article dans une revue hal-02143627v1

Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study

François Goldwasser , Pascale Vinant , Régis Aubry , Philippe Rochigneux , Yvan Beaussant et al.

Cancer, 2018, 124 (14), pp.3044-3051. ⟨10.1002/cncr.31536⟩

Article dans une revue hal-03689951v1

Hospital end-of-life care in haematological malignancies

Yvan Beaussant , Etienne Daguindau , Adrien Chauchet , Philippe Rochigneux , Christophe Tournigand et al.

BMJ Palliative and supportive care, 2018, 8 (3), pp.314-324. ⟨10.1136/bmjspcare-2017-001446⟩

Article dans une revue hal-03689944v1

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

Philippe Rochigneux , Jeanne Thomassin-Piana , Sophy Laibe , Serge Brunelle , Naji Salem et al.

BMC Cancer, 2018, 18 (1), pp.1159. ⟨10.1186/s12885-018-5049-3⟩

Article dans une revue hal-04515988v1

Gastrointestinal Stromal Tumour with Synchronous Bone Metastases: A Case Report and Literature Review

Philippe Rochigneux , Lénaig Mescam-Mancini , Delphine Perrot , Erwan Bories , Laurence Moureau-Zabotto et al.

Case Reports in Oncology, 2017, 10 (1), pp.66-76. ⟨10.1159/000455188⟩

Article dans une revue hal-03623722v1

Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie

Ronan Flippot , Christophe Massard , Édouard Auclin , David Azria , Heloise Bourien et al.

Bulletin du Cancer, 2017, 104 (9), pp.735-743. ⟨10.1016/j.bulcan.2017.07.003⟩

Article dans une revue hal-02370054v1

Use of chemotherapy near the end of life: what factors matter?

Philippe Rochigneux , J.L. Raoul , Y. Beaussant , R. Aubry , F. Goldwasser et al.

Annals of Oncology, 2017, 28 (4), pp.809-817. ⟨10.1093/annonc/mdw654⟩

Article dans une revue hal-03689961v1

Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study

Emmanuelle Kempf , Christophe Tournigand , Philippe Rochigneux , Régis Aubry , Lucas Morin

European Journal of Cancer, 2017, 79, pp.31-40. ⟨10.1016/j.ejca.2017.03.029⟩

Article dans une revue hal-03560299v1

Les actualités marquantes du congrès Targeted Anticancer Therapies — TAT 2016

R. Flippot , I. Bouallagui , P. Du Rusquec , P. Gougis , C. Henon et al.

Oncologie, 2016, 18 (7-8), pp.451-462. ⟨10.1007/s10269-016-2651-3⟩

Article dans une revue hal-03689977v1

End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study

I. Gallais Sérézal , Y. Beaussant , Philippe Rochigneux , C. Tournigand , R. Aubry et al.

British Journal of Dermatology, 2016, 175 (3), pp.583-592. ⟨10.1111/bjd.14631⟩

Article dans une revue istex hal-03689969v1